Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Trial Profile

Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Panitumumab (Primary) ; Carboplatin; Gemcitabine
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 19 May 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.
    • 21 Aug 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center record: 10-103).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top